ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Afinitor Suspension Approved For Rare Pediatric Brain Tumor

August 31, 2012

M.D. Anderson signs collaboration agreement with Institut Gustave Roussy.

February 13, 2004

DeVita On Problems Of Drug Response: There May be Tw Populations Of Cells; Molecular Medicine will Change Treatment

December 13, 1991

Cranial Radiation Eliminated With Personalized Chemo

August 28, 2009

Two Workshops To Look For New Research Areas

October 29, 1976

Avastin May Trigger Two FDA Decisions: One On Approval, Another On Withdrawal

September 3, 2010